Fractyl Health (NASDAQ:GUTS) CEO Buys $18,250.00 in Stock

Fractyl Health, Inc. (NASDAQ:GUTS) CEO Harith Rajagopalan acquired 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 10th. The shares were purchased at an average cost of $0.73 per share, for a total transaction of $18,250.00. Following the completion of the acquisition, the chief executive officer owned 540,557 shares in the company, valued at $394,606.61. This represents a 4.85% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Fractyl Health Stock Performance

Shares of NASDAQ GUTS opened at $0.85 on Friday. The stock has a market cap of $134.85 million, a price-to-earnings ratio of -0.66 and a beta of 2.34. The company has a current ratio of 4.28, a quick ratio of 4.28 and a debt-to-equity ratio of 1.41. Fractyl Health, Inc. has a 1-year low of $0.38 and a 1-year high of $2.45. The stock’s 50-day moving average is $0.69 and its 200 day moving average is $1.07.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.23. On average, sell-side analysts anticipate that Fractyl Health, Inc. will post -0.6 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on GUTS. Wall Street Zen upgraded Fractyl Health from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Fractyl Health in a research note on Tuesday, May 12th. HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a research note on Thursday, June 4th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a research note on Thursday, March 26th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $5.40.

Institutional Trading of Fractyl Health

Several large investors have recently bought and sold shares of GUTS. Woodline Partners LP boosted its position in Fractyl Health by 47.2% during the 1st quarter. Woodline Partners LP now owns 516,921 shares of the company’s stock valued at $615,000 after acquiring an additional 165,786 shares in the last quarter. Qube Research & Technologies Ltd bought a new stake in Fractyl Health during the 2nd quarter valued at approximately $129,000. General Catalyst Group Management LLC bought a new stake in Fractyl Health during the 2nd quarter valued at approximately $7,912,000. Jane Street Group LLC bought a new stake in Fractyl Health during the 2nd quarter valued at approximately $31,000. Finally, Osaic Holdings Inc. boosted its position in Fractyl Health by 460.3% during the 2nd quarter. Osaic Holdings Inc. now owns 59,645 shares of the company’s stock valued at $97,000 after acquiring an additional 49,000 shares in the last quarter.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.